Evidence map›Paper›PMID 40192757›Full record

ArticleAnnals of hematology2025

Molecular response with asciminib 20 mg QD in a patient intolerant to multiple TKIs.

Ruth Stuckey, Laura Navarrete Bullón, Asunción Borrero Borrego, Violeta Vidal Ballester, Carlos Rodríguez-Medina, Alejandro Morales Curbelo, Leslie González Pinedo, Melissa Torres Ochando, Alvaro Veiga Vaz, María Del Mar Perera and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ruth StuckeyHematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.ORCID http://orcid.org/0000-0001-6955-2290
Laura Navarrete BullónHematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.
Asunción Borrero BorregoPerelman School of Medicine, Department of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA, United States of America.ORCID http://orcid.org/0000-0002-0293-5614
Violeta Vidal BallesterHematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.
Carlos Rodríguez-MedinaHematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.
Alejandro Morales CurbeloHematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.
Leslie González PinedoHematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.
Melissa Torres OchandoHematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.ORCID http://orcid.org/0000-0001-5465-3355
Alvaro Veiga VazHematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.
María Del Mar PereraHematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.ORCID http://orcid.org/0009-0006-9649-4050
Cristina Bilbao-SieyroHematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.ORCID http://orcid.org/0000-0002-4796-1445
Juan Francisco López RodríguezHematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.ORCID http://orcid.org/0000-0002-4862-4088
Adrián Segura-DíazHematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain. asegdia@gobiernodecanarias.org.ORCID http://orcid.org/0000-0002-2070-3227
María Teresa Gómez-CasaresHematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain.ORCID http://orcid.org/0000-0003-0505-5126

Funding

Fundación Canaria Instituto de Investigación Sanitaria de Canarias PIFIISC22/35
6 · The paper itself

Abstract

This case highlights a young CML patient who achieved a major molecular response (MMR) after just four months with a subtherapeutic dose of asciminib. The patient could not tolerate full-dose asciminib, or the full dose of two previous tyrosine kinase inhibitors (TKI) due to myelotoxicity, but blood counts recovered rapidly upon TKI suspension and reduced dosing enabled sustained treatment. This is the second reported case of the use of 20 mg QD asciminib, four times below the recommended dose, and the first to demonstrate efficacy at this dose. The study emphasizes asciminib's potential for overcoming treatment challenges associated with multi-resistant/intolerant CML patients.

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsPyrazolesDrug Resistance, NeoplasmFusion Proteins, bcr-ablHumansNiacinamideTreatment OutcomeasciminibFusion Proteins, bcr-ablNiacinamideProtein Kinase InhibitorsPyrazolesAsciminibCytopeniaSubtherapeutic dosingTyrosine kinase inhibitors (TKIs)

Identifiers

PMID40192757
PMCPMC12141399

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.